TWINRIX Accelerated dosing protects against both Hepatitis A and B.
Three doses given within three weeks followed by a booster dose at 12 month delivers a sustained immune response - comparable to monovalent vaccines.
Read about Hepatitis A and B
here.
Important Safety Information TWINRIX is contraindicated in people with hypersensitivity to any component of the vaccine, including yeast and neomysin. In clinical trials with TWINRIX, the most common solicited adverse events were soreness at the injection site, redness at the injection site, headache and fatigue. They were mild and self-limiting and did not last more than 48 hours. As with any vaccine, rare adverse events may occur. As with any vaccine, TWINRIX may not protect 100% of individuals receiving the vaccine.
TWINRIX is registered trademark of GlaxoSmithKline. See the company's website for more detailed information.